tesaglitazar has been researched along with tzd 18 in 1 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (tzd 18) | Trials (tzd 18) | Recent Studies (post-2010) (tzd 18) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 6 | 0 | 1 |
| Protein | Taxonomy | tesaglitazar (IC50) | tzd 18 (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.057 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 0.028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
1 review(s) available for tesaglitazar and tzd 18
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |